Table 1.
Laboratory findings of patients with VITT after ChAdOx1 nCoV-19 vaccination according to outcome
| Laboratory findings | Total patients (n = 64a) | Survivors (n = 40) | Non-survivors (n = 23) | P-value |
|---|---|---|---|---|
| Platelet (n = 62) | ||||
| Platelet count (cells/mm3) | 35 000 (16 750, 70 250) | 40 000 (26 000, 70 000) | 19,000 (13,750, 75,750) | 0.121 |
| Platelet <25 × 103/μL | 22/62 (35.5) | 9/39 (23.1) | 13/22 (60.9) | 0.007 |
| PT (n = 41) | ||||
| PT (s) (n = 10) | 13.35 (12.95, 14.95) | 14.10 (13.15, 20.40) | 13.10 (12.80, 15.00) | 0.366 |
| PT INR (n = 28) | 1.20 (1.10, 1.40) | 1.20 (1.10, 1.30) | 1.20 (1.10, 1.66) | 0.488 |
| PT, abnormal valueb | 31/41 (70.5) | 18/27 (66.7) | 13/17 (76.5) | 0.735 |
| aPTT (n = 43) | ||||
| aPTT (s) (n = 23) | 29.90 (25.00, 39.43) | 28.70 (24.00, 37.35) | 32.70 (27.75, 43.85) | 0.258 |
| aPTT ratio (n = 14) | 1.05 (0.98, 1.33) | 1.05 (0.98, 1.33) | 1.05 (0.91, 1.55) | 0.962 |
| aPTT, abnormal valueb | 16/43 (37.2) | 10/26 (38.5) | 6/17 (35.3) | 1.000 |
| Fibrinogen (n = 50) | ||||
| Fibrinogen (mg/dL) | 140.00 (110.00, 262.50) | 210.00 (120.00, 345.00) | 120.00 (80.00, 140.00) | 0.003 |
| Fibrinogen <150 mg/dL | 26/50 (52.0) | 11/31 (35.5) | 15/19 (78.9) | 0.004 |
| D-dimer (n = 55) | ||||
| D-dimer/upper limit of normal range | 62.60 (20.80, 70.40) | 45.80 (16.30, 70.40) | 70.00 (32.22, 79.05) | 0.143 |
| D-dimer, abnormal value (>500 mg/L, FEU) | 55/55 (100) | 37/37 (100) | 17/17 (100) | 1.000 |
| Anti-PF4/heparin antibody ELISA (n = 47) | ||||
| Anti-PF4/heparin antibody ELISA OD | 2.16 (1.14, 2.92) | 1.44 (0.64, 2.63) | 2.26 (1.40, 3.13) | 0.103 |
| Anti-PF4/heparin antibody ELISA positive | 46/47 (97.9) | 26/27 (96.3) | 19/19 (100.0) | 1.000 |
| Functional HIT Assay (n = 21) | ||||
| Platelet activation assay | 19/21 (90.5) | 9/10 (90.0) | 9/10 (90.0) | 1.000 |
Values are given as n/N (%) or median (IQR).
IQR, interquartile range; ELISA, enzyme-linked immunosorbent assay; HIT, heparin-induced thrombocytopenia; OD, optical density; FEU, fibrinogen equivalent unit.
a
One patient had an unknown outcome.
b
PT (prothrombin time)/PT (s) normal range: 10.0–12.0 s/PT INR normal range: 0.9–1.1.
††
aPTT (activated partial thromboplastin time)/aPTT (s) normal range: 25.0–35.0 s/aPTT ratio normal range: 0.8–1.2.